According to the Phase 3b, double-blind, placebo-controlled STRIDE study, Ozempic (1 mg) resulted in a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference of 39.9 meters on a steep incline compared to placebo at week 52 in adults with T2DM and PAD. If approved, Ozempic will be the only GLP-1 receptor agonist indicated for the treatment of PAD in patients with T2DM
The anti-inflammatory effects associated with weight loss and metabolic improvement may also be beneficial, as chronic inflammation plays a role in AMD pathogenesis
Hyaluronic acid as a non-invasive biomarker of liver fibrosis
arrow_right Continual portfolio review with intra-day tax-loss harvesting arrow_right Select from integrated major branded indexes arrow_right Index blending and custom benchmark development arrow_right Portfolio customization with over 70 preset options arrow_right Capital gains budgeting arrow_right Access to intuitive advisor user interface arrow_right On-demand quarterly performance reports arrow_right Real-time portfolio transition analysis and reporting arrow_right Implementation specialists to support client onboarding arrow_right Solutions for Institutional and tax-exempt organizations arrow_right Fund with cash or in-kind securities Institutional Capabilities We bring a wealth of institutional investment experience, a consultative approach, and a strong commitment to crafting thoughtful solutions tailored to your unique needs
SUPERFOODS AND ANTIOXIDANTS - Glutathione tablets are potent antioxidants that promote the reduction of oxidative stress caused by free radicals
